Literature DB >> 2871035

High-performance liquid chromatographic determination of alfuzosin in biological fluids with fluorimetric detection and large-volume injection.

P Guinebault, M Broquaire, C Colafranceschi, J P Thénot.   

Abstract

A high-performance liquid chromatographic method has been developed for the determination of alfuzosin, a new antagonist of alpha 1 post-synaptic adrenergic receptors, in blood, plasma or urine. With fluorimetric detection and the large volume injection technique, the limit of detection in plasma is 0.5-1 ng ml-1, which is sensitive enough for pharmacokinetic studies in man. The calibration graph is linear between 1 and 200 ng ml-1 in blood plasma, with coefficients of variation of 6.2 and 1%, respectively. In urine, the linearity range is 0.05-10 micrograms ml-1; at the lowest concentration, the coefficient of variation is about 10%. A constant plasma/blood concentration ratio (1.25 +/- 0.05) allows the measurement of drug in either fluid. In blood or plasma, alfuzosin is stable at 37 degrees C for 24 h and at -20 degrees C for 6 months. As expected for reversed-phase chromatography, the retention times of alfuzosin and a few of its analogues decrease inversely with the concentration of acetonitrile in the mobile phase. However, as this concentration reaches about 75%, the retention times increase sharply. This U-shaped curve may be explained by interactions of the amino groups with silanol groups of the stationary phase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871035     DOI: 10.1016/s0021-9673(01)87106-5

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.

Authors:  S Leto di Priolo; P Priore; G Cocco; C Sfrisi; J L Cazor
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.

Authors:  M G Scott; A H Deering; M T McMahon; D W Harron; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

4.  In vitro-in vivo correlation evaluation of generic alfuzosin modified release tablets.

Authors:  Utpal Kumar Sanki; Badal Kumar Mandal
Journal:  ISRN Toxicol       Date:  2012-11-20

5.  Spectrophotometric Determination of Alfuzosin HCl in Pharmaceutical Formulations with some Sulphonephthalein Dyes.

Authors:  Safwan Ashour; M Fawaz Chehna; Roula Bayram
Journal:  Int J Biomed Sci       Date:  2006-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.